Mazdutide
Dual GLP-1 / glucagon receptor agonist investigated for metabolic and weight outcomes.
Research overview
Mazdutide is an investigational peptide therapeutic developed for the treatment of type 2 diabetes and obesity. It is classified as a long-acting, dual-receptor agonist, meaning it is designed to activate two different hormone receptors simultaneously.
The mechanism of action for Mazdutide involves functioning as an agonist for both the Glucagon-like peptide-1 (GLP-1) receptor and the Glucagon receptor. The activation of the GLP-1 receptor promotes satiety, slows gastric emptying, and improves glucose-dependent insulin secretion, similar to established drugs in its class. The concurrent activation of the glucagon receptor is proposed to increase energy expenditure and enhance fat metabolism. The therapeutic hypothesis is that this combined action on both pathways will lead to more significant weight loss and better metabolic control than targeting the GLP-1 receptor alone.
Peer-Reviewed Research (PubMed)
Selected landmark / highly-cited studies indexed on PubMed.
- 1.Efficacy and safety of mazdutide in Chinese patients with overweight or obesity: a randomised, double-blind, placebo-controlled phase 2 trialJi L, et al. — The Lancet Diabetes & Endocrinology, 2023
- 2.
- 3.Most cited mazdutide / IBI362 studies (PubMed)Multiple authors — PubMed search
Studied benefits
- Dual GLP-1 and glucagon receptor activation
- Investigated for greater weight loss vs GLP-1 alone
- Improves lipid metabolism
- Once-weekly profile in studies
Trusted U.S. research-peptide suppliers
We source and benchmark against established U.S.-based research-peptide manufacturers and distributors. Each supplier below operates under cGMP-aligned synthesis with documented CoA, HPLC, and mass-spec validation for research use only.
Logos are property of their respective owners and shown for reference only. Listing does not imply endorsement or an exclusive supply relationship.
Inquire about Mazdutide
Share your research context so our team can recommend the right purity grade, documentation, and quantity. A scientific contact responds personally.
Related peptides
Modified hGH fragment (176–191) studied for fat metabolism without affecting glucose or IGF-1.
Long-acting amylin analog investigated for appetite regulation and weight management, often paired with GLP-1 agonists.
C-terminal hGH fragment studied for fat-loss effects without growth or insulin-axis impact.